Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Review

A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma

Authors: Shaojie Jiang, Yingxia Liu, Linhai Wang, Chenyang Duan, Mengying Liu

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Objective

To evaluate the efficacy and safety of adjuvant IFN therapy for viral hepatitis-related hepatocellular carcinoma (HCC) after treatment with surgical resection or transarterial chemoembolization (TACE).

Methods

Controlled trials of adjuvant treatment with IFN for patients with HCC published between 2000 and 2012 were searched electronically in MEDLINE, PubMed, Cochrane Library, and EMBASE databases. According to the heterogeneity of the studies, two different models - the fixed-effect model and the random-effect model - were applied to analyze the results.

Results

Ten trials were screened according to inclusion and exclusion standards. Eight randomized, controlled trials and two non-randomized, controlled trials were included. These ten trials with a total of 1,029 subjects were eventually involved in the meta-analysis; 528 HCC patients were treated with adjuvant treatment with IFN and 501 patients with placebo. Compared to the control group, the recurrence rates of HCC in IFN group were significantly lower (odds ratio (OR) = 0.66; 95% confidence interval (CI) = 0.50 to 0.86; P = 0.02), especially after TACE treatment according to subgroup analysis (OR = 0.73; 95% CI = 0.52 to 1.01; P = 0.06 for surgical resection; and OR = 0.54; 95% CI = 0.33 to 0.86, P = 0.01 for TACE). The death rates in the IFN group also significantly decreased according to not only total events analysis (OR = 0.42; 95% CI = 0.32 to 0.56; P < 0.00001) but also subgroup analysis (OR = 0.51; 95% CI = 0.36 to 0.72; P = 0.0002 for surgical resection; and OR = 0.33; 95% CI = 0.21 to 0.50; P < 0.00001 for TACE).

Conclusions

Adjuvant IFN therapy may significantly reduce the recurrence rates of patients with viral hepatitis-related HCC and improve the survival of patients after surgical resection or TACE. The ideal dose mostly selected is 3 MIU/ml, three times per week, which can make patients tolerate the adverse reactions of IFN better and maintain effective concentrations for a long time.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol. 2007, 132 (7): 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRef El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol. 2007, 132 (7): 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRef
2.
go back to reference Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362 (9399): 1907-1917. 10.1016/S0140-6736(03)14964-1.CrossRefPubMed Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362 (9399): 1907-1917. 10.1016/S0140-6736(03)14964-1.CrossRefPubMed
3.
go back to reference Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Müting D, Rambach W: Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg. 1991, 78 (4): 459-462. 10.1002/bjs.1800780423.CrossRefPubMed Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Müting D, Rambach W: Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg. 1991, 78 (4): 459-462. 10.1002/bjs.1800780423.CrossRefPubMed
4.
go back to reference Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999, 229 (3): 322-330. 10.1097/00000658-199903000-00004.PubMedCentralCrossRefPubMed Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999, 229 (3): 322-330. 10.1097/00000658-199903000-00004.PubMedCentralCrossRefPubMed
5.
go back to reference Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005, 25 (2): 181-200. 10.1055/s-2005-871198.CrossRefPubMed Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005, 25 (2): 181-200. 10.1055/s-2005-871198.CrossRefPubMed
6.
go back to reference von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003, 95 (6): 437-448. 10.1093/jnci/95.6.437.CrossRefPubMed von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003, 95 (6): 437-448. 10.1093/jnci/95.6.437.CrossRefPubMed
7.
go back to reference Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003, 7 (5): 587-594. 10.1016/S1091-255X(03)00072-6.CrossRefPubMed Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003, 7 (5): 587-594. 10.1016/S1091-255X(03)00072-6.CrossRefPubMed
8.
go back to reference Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatol. 2000, 32 (2): 228-232. 10.1053/jhep.2000.9409.CrossRef Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatol. 2000, 32 (2): 228-232. 10.1053/jhep.2000.9409.CrossRef
9.
go back to reference Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002, 89 (4): 418-422. 10.1046/j.0007-1323.2001.02054.x.CrossRefPubMed Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002, 89 (4): 418-422. 10.1046/j.0007-1323.2001.02054.x.CrossRefPubMed
10.
go back to reference Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003, 138 (4): 299-306. 10.7326/0003-4819-138-4-200302180-00008.CrossRefPubMed Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003, 138 (4): 299-306. 10.7326/0003-4819-138-4-200302180-00008.CrossRefPubMed
11.
go back to reference Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004, 100 (2): 376-382. 10.1002/cncr.20004.CrossRefPubMed Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004, 100 (2): 376-382. 10.1002/cncr.20004.CrossRefPubMed
12.
go back to reference Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y: Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama. 2005, 59 (5): 217-224.PubMed Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y: Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama. 2005, 59 (5): 217-224.PubMed
13.
go back to reference Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatol. 2006, 44 (6): 1543-1554. 10.1002/hep.21415.CrossRef Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatol. 2006, 44 (6): 1543-1554. 10.1002/hep.21415.CrossRef
14.
go back to reference Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006, 132 (7): 458-465. 10.1007/s00432-006-0091-y.CrossRefPubMed Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006, 132 (7): 458-465. 10.1007/s00432-006-0091-y.CrossRefPubMed
15.
go back to reference Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007, 245 (6): 831-842. 10.1097/01.sla.0000245829.00977.45.PubMedCentralCrossRefPubMed Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007, 245 (6): 831-842. 10.1097/01.sla.0000245829.00977.45.PubMedCentralCrossRefPubMed
16.
go back to reference Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D: Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009, 24 (8): 1437-1444. 10.1111/j.1440-1746.2009.05863.x.CrossRefPubMed Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D: Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009, 24 (8): 1437-1444. 10.1111/j.1440-1746.2009.05863.x.CrossRefPubMed
17.
go back to reference Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ: A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010, 17 (1): 179-185. 10.1245/s10434-009-0694-z.CrossRefPubMed Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ: A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010, 17 (1): 179-185. 10.1245/s10434-009-0694-z.CrossRefPubMed
18.
go back to reference Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T: Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 2012, 59 (114): 529-532.PubMed Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T: Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 2012, 59 (114): 529-532.PubMed
19.
go back to reference Marrero JATM: Current Treatment Approaches in HCC. Clin Adv Hematol Oncol. 2013, 5 (4): 15-18. Marrero JATM: Current Treatment Approaches in HCC. Clin Adv Hematol Oncol. 2013, 5 (4): 15-18.
20.
go back to reference Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005, 48 (1): 64-70. 10.1159/000082097.CrossRefPubMed Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005, 48 (1): 64-70. 10.1159/000082097.CrossRefPubMed
21.
go back to reference Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA: Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol. 2003, 18 (6): 630-637. 10.1046/j.1440-1746.2003.03019.x.CrossRefPubMed Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA: Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol. 2003, 18 (6): 630-637. 10.1046/j.1440-1746.2003.03019.x.CrossRefPubMed
22.
go back to reference Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, Yuan Z: Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol. 2013, 14 (8): 793-803. 10.1038/ni.2647.CrossRefPubMed Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, Yuan Z: Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol. 2013, 14 (8): 793-803. 10.1038/ni.2647.CrossRefPubMed
23.
go back to reference Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, Chen J, Xue XB, Fan J, Zhang H: Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer. 2012, 11 (1): 31-10.1186/1476-4598-11-31.PubMedCentralCrossRefPubMed Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, Chen J, Xue XB, Fan J, Zhang H: Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer. 2012, 11 (1): 31-10.1186/1476-4598-11-31.PubMedCentralCrossRefPubMed
24.
go back to reference Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatol. 2000, 32 (1): 43-48.CrossRef Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatol. 2000, 32 (1): 43-48.CrossRef
25.
go back to reference Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY: Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2013, 21 (5): 335-339.PubMed Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY: Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2013, 21 (5): 335-339.PubMed
26.
go back to reference Ormeci N: Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol. 2003, 17: 651-658. 10.1046/j.1472-8206.2003.00194.x.CrossRefPubMed Ormeci N: Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol. 2003, 17: 651-658. 10.1046/j.1472-8206.2003.00194.x.CrossRefPubMed
27.
go back to reference Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001, 3: 196-197.CrossRef Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001, 3: 196-197.CrossRef
28.
go back to reference Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J: A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006, 33: 121-128. 10.1016/j.cyto.2005.08.011.CrossRefPubMed Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J: A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006, 33: 121-128. 10.1016/j.cyto.2005.08.011.CrossRefPubMed
Metadata
Title
A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma
Authors
Shaojie Jiang
Yingxia Liu
Linhai Wang
Chenyang Duan
Mengying Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-240

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue